The role of radiofrequency ablation for treatment of metachronous isolated hepatic metastasis from colorectal cancer.
We investigated recurrence pattern and oncologic outcomes after treatment of metachronous isolated liver metastases from colorectal cancer according to treatment modality.We retrospectively analyzed 123 patients treated with hepatic resection and 82 patients treated with radiofrequency ablation (RFA) for metachronous isolated hepatic metastasis from colorectal cancer (HMCRC). We compared clinicopathological data, recurrence pattern, and recurrence-free survival (RFS) rates after the treatment of hepatic metastasis between patients treated with RFA and resection.The patients in the 2 groups were similar in gender, location of primary tumor, disease-free interval to hepatic metastasis, pathologic stage of primary tumor, and number of hepatic metastasis. The age was older in RFA group but it was not statistically different. The mean diameter of the largest hepatic mass was greater in the resection group than in the RFA group (3.1 vs 1.9 cm, P < 0.001). Chemotherapy after the treatment of hepatic metastasis was more commonly given in hepatic resection group (76.4% vs 62.2%, P = 0.04). Recurrence after the treatment of hepatic metastasis was not significantly different between the 2 groups (54.5% vs 65.9% in the resection and RFA groups). However, intrahepatic recurrence without extra-hepatic metastases was more common in the RFA group than in the resection group (47.5% vs 12.1%, P < 0.001). The RFS rate after the treatment of hepatic metastasis was significantly higher in resection group (48.6% vs 33.7%, P = 0.015). The size and number of hepatic metastasis, primary tumor stage, disease-free interval to hepatic metastasis, and the modality of treatment (RFA vs resection) for hepatic metastasis were confirmed as associated factors with re-recurrence after the treatment of hepatic metastasis. Among patients with solitary hepatic metastases of ≤3 cm, marginal recurrence was higher in the RFA group (3% vs 17.2%) and re-RFA was performed to achieve comparable recurrence rate (3% vs 5.2%, P = 0.662), the RFS rate was not different between the resection and RFA group (52.4% vs 53.4%, P = 0.491).Surgical resection for HMCRC showed higher RFS. However, the RFS rate in patients with a solitary hepatic metastasis of ≤3 cm was similar between the resection and RFA groups.
aDivision of Colon and Rectal Surgery bDepartment of Radiology and Research Institute of Radiology cDivision of Hepatobiliary Surgery and Liver Transplantation dDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Byoung Chul
BC
Lee
Hyun Gu
HG
Lee
In Ja
IJ
Park
So Yeon
SY
Kim
Ki-Hun
KH
Kim
Jae Hoon
JH
Lee
Chan Wook
CW
Kim
Jong Lyul
JL
Lee
Yong Sik
YS
Yoon
Seok-Byung
SB
Lim
Chang Sik
CS
Yu
Jin Cheon
JC
Kim
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017115:Catheter Ablation / Q000379:methods*; D015179:Colorectal Neoplasms / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000556:secondary / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
Hepatogastroenterology. 2015 Mar-Apr;62(138):373-7
25916066
Cancer. 2000 Jul 15;89(2):276-84
10918156
Am J Surg. 2009 Jun;197(6):728-36
18789428
J Gastrointest Surg. 2011 Feb;15(2):378-87
21061179
World J Gastroenterol. 2014 Jan 14;20(2):525-31
24574721
Cardiovasc Intervent Radiol. 2008 Sep-Oct;31(5):948-56
18506519
Ann Surg. 2005 May;241(5):715-22, discussion 722-4
15849507
Ann Surg Oncol. 2008 Oct;15(10 ):2757-64
18618182
Ann Surg Oncol. 2008 Jan;15(1):144-57
17906898
Surg Clin North Am. 1997 Feb;77(1):27-48
9092116
Br J Surg. 2003 Oct;90(10):1240-3
14515293
Hepatogastroenterology. 2014 Mar-Apr;61(130):436-41
24901157
Korean J Gastroenterol. 2012 Mar;59(3):218-23
22460570
Ann Surg Oncol. 2004 May;11(5):500-5
15078636
J Gastrointest Surg. 2002 Mar-Apr;6(2):255-63
11992812
Med Ultrason. 2014 Jun;16(2):145-51
24791846
Radiology. 2014 Oct;273(1):241-60
24927329
Cancer Control. 2006 Jan;13(1):48-51
16508626
J Clin Gastroenterol. 2008 Sep;42(8):945-9
18438208
Ann Surg. 2006 Mar;243(3):321-8
16495695
Eur J Surg Oncol. 2007 Feb;33(1):67-71
17174059
Ann Surg Oncol. 2008 Jan;15(1):227-32
17882491
Ann Surg. 2007 Oct;246(4):559-65; discussion 565-7
17893492
Radiology. 1997 Nov;205(2):367-73
9356616
Radiology. 2009 Dec;253(3):861-9
19709994
PLoS One. 2012;7(9):e45493
23029051
Arch Surg. 2006 May;141(5):460-6; discussion 466-7
16702517
Cancer. 1993 Jun 15;71(12 Suppl):4252-66
8508388
J Korean Surg Soc. 2011 Jul;81(1):25-34
22066097
J Gastrointest Surg. 2001 Sep-Oct;5(5):477-89
11985998
Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7
15166961